CNS Pharmaceuticals, Inc.
CNSP
$1.12
-$0.005-0.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 21.18% | 8.36% | 8.77% | -2.40% | -23.42% |
| Total Depreciation and Amortization | -19.05% | -39.29% | -53.33% | -61.86% | -64.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.38% | 44.27% | -25.51% | -20.64% | -16.43% |
| Change in Net Operating Assets | -199.86% | -59.47% | 18.80% | 24.25% | 16.90% |
| Cash from Operations | -21.03% | -1.94% | 12.88% | -1.64% | -33.93% |
| Capital Expenditure | -7.69% | -29.41% | -160.00% | 11.36% | 11.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.69% | -29.41% | -160.00% | 11.36% | 11.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 31.43% | 23.90% | 15.25% | 6.41% | -2.60% |
| Issuance of Common Stock | 343.23% | 152.96% | 5.63% | 63.03% | -67.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 67.08% | -- | -- | -- | -- |
| Cash from Financing | 396.63% | 159.78% | 3.96% | 64.99% | -70.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 162.20% | 199.11% | 40.43% | 41.40% | -288.22% |